MoUJun 25, 2026, 07:32 AM
BriaCell signs MoU with Uneedle for Bria-IMT microneedle tech
AI Summary
BriaCell Therapeutics Corp. has signed a Memorandum of Understanding (MoU) with Uneedle, a microneedle-based drug-delivery device company. This non-binding agreement supports the continued use and commercial readiness of Uneedle's proprietary microneedle technology for the intradermal administration of BriaCell's lead Phase 3 clinical candidate, Bria-IMT, for metastatic breast cancer. The technology is already being used in BriaCell's ongoing pivotal Phase 3 study and aims to provide faster, more convenient, and patient-friendly treatment.
Key Highlights
- BriaCell entered a non-binding MoU with Uneedle for microneedle technology.
- Agreement supports continued use and commercial readiness of Uneedle's technology for Bria-IMT.
- Uneedle's microneedle technology is used in BriaCell's pivotal Phase 3 study for Bria-IMT.
- Bria-IMT is BriaCell's lead Phase 3 clinical candidate for metastatic breast cancer.
- The technology aims for faster, more convenient, and patient-friendly administration.
- MoU establishes a plan for scaling microneedle devices for commercial quantities.
- All activities are contingent upon successful regulatory approval of Bria-IMT.
Price Impact
More from BCTX